Announcements Trials

Browse Landscape

Phase

Phase 2 9 Phase 1 8 Phase 1/2 3 Phase NA 1 Phase 4 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 2 Breast Neoplasms 2 Thyroid Neoplasms 1 Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 BRCA or HRR+ Mutated Ovarian Cancer Patients 1

Interventions

Dexamethasone 8 Oxycodone 6 Epoetin Alfa 5 Propofol 4 Palonosetron 4 Meropenem 4 Zoledronic Acid 3 Vancomycin 3 Sevoflurane 3 Ondansetron 3 Naloxone 3 Everolimus 3 Ciprofloxacin 3 Cholecalciferol 3 Ceftazidime 3 Cefepime 3 Calcium Dobesilate 3 Bevacizumab 3 Aspirin 3 Aprepitant 3 peginterferon alfa-2a 2 edoxaban 2 apixaban 2 apatinib 2 Vitamin B 12 2 Vincristine 2 Tobacco Use Cessation Devices 2 Teicoplanin 2 Tablets 2 Surgical Procedures, Operative 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Neoplasms × olaparib × Clear all

NCT05078671 2024-06-12

PROACTIVE

Radboud University Medical Center

Phase 4 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡